Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

PALO ALTO, Calif.: PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a...

Click to view original post